Saturday, October 16, 2021

AstraZeneca to test combining COVID-19 vaccine with Russian shot


AstraZeneca will start clinical trials to test a combination of its experimental COVID-19 vaccine with Russia’s Sputnik V shot aimed at boosting the efficacy of the British drugmaker’s vaccine, Russia’s sovereign wealth fund said on Friday.

Trials will start by the end of the year, said the RDIF wealth fund, which has funded Sputnik V, named after the Soviet-era satellite that triggered the space race.

In a statement on Friday, AstraZeneca said it was considering how it could assess combinations of different vaccines, and would soon begin exploring with Russia’s Gamaleya Institute, which developed Sputnik V, whether two common cold virus-based vaccines could be successfully combined.

It did not give further details.

The co-operation between one of Britain’s most valuable listed companies and the state-backed Russian science research institute highlights the pressure to develop an effective shot to fight the pandemic that has killed over 1.5 million people.

The move is likely to be seen in Moscow as a long-awaited vote of confidence by a Western manufacturer in Sputnik V.

Its Russian developers say clinical trials, still underway, have shown it has an efficacy rate of over 90%, higher than AstraZeneca’s own vaccine and similar to U.S. rivals Pfizer and Moderna.

Some Western scientists have raised concerns about the speed at which Russia has worked, giving the regulatory go-ahead for its vaccines and launching large-scale vaccinations with Sputnik V before full trials to test its safety and efficacy have been completed.

The prospective tie-up comes as AstraZeneca, once seen as a frontrunner in the vaccine race, prepares for further tests to confirm whether its shot could be 90% effective, potentially slowing its rollout.

The average efficacy rate was 70.4% in interim late-stage data.

Both projects are using harmless adenoviruses as vehicles to bring genetic instructions into the body to prompt cells to produce vaccine proteins, an approach that has previously been used in an Ebola vaccine.

The developers of Sputnik V suggested on Twitter last month that AstraZeneca try the combination.

“The decision by AstraZeneca to carry out clinical trials using one of two vectors of Sputnik V in order to increase its own vaccine’s efficacy is an important step towards uniting efforts in the fight against the pandemic,” said RDIF head Kirill Dmitriev in a statement.

The partnership may draw scrutiny after Britain said in July hackers backed by the Russian state were trying to steal COVID-19 vaccine and treatment research from academic and pharmaceutical institutions around the world. The Kremlin rejected the Western allegations.

The news came as Sanofi and GlaxoSmithKline said clinical trials of their COVID-19 vaccine showed an insufficient immune response in older people.





Source link

Latest Articles

Widely used chemical linked to 1,00,000 US deaths per year: Study

NEW YORK: Daily exposure to phthalates, a group of chemicals used in everything from plastic containers to makeup, may lead to approximately 100,000 deaths...

Foods to Reduce Inflammation and Strengthen the Immune System

Did you know that you can greatly reduce inflammation and boost your immune system by simply incorporating more anti-inflammatory foods and beverages into your...

Personal Selling

INTRODUCTION Early sellers and traders were not held in high esteem. The Roman word for salesman meant ‘Cheater’ and...

Building Muscle on a Vegan Diet

There are a lot of  misconceptions surrounding veganism. The notion that those who practice it are lacking in protein and therefore muscles is the...

Electrodes in brain new hope for severe cases of epilepsy

Neurosurgeons at All India Institute of Medical Sciences have devised a new technique for operating on children suffering from a severe form of epilepsy...